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The varicella-zoster virus (VZV) immediate-early (IE) open reading frame 62 (ORF62) promoter sequence contains a CCAAT
box, located between positions 0117 and 0113. Mutation of this motif resulted in a five-fold increase of promoter activity.
In mobility shift assays, we demonstrated that NF-Y, a CCAAT box-binding protein critical for the expression of diverse
eukaryotic genes, binds to this motif. Thus, the VZV IE ORF62 promoter contains a negative regulatory element that binds
the ubiquitous transcriptional factor NF-Y. q 1995 Academic Press, Inc.
The CCAAT box is an important promoter element in VZV ORF62 promoter in transient expression assays
(17, 20–22); ORF62 protein transrepresses or transacti-diverse eukaryotic protein coding genes and functions
in both ubiquitous and cell-type- or cell-cycle-specific vates its own promoter, depending on the cell type (23,
24). Lymphocyte- and neuronal cell-specific octamer-expression (for review, see Ref. 1). Several proteins that
mediate CCAAT box function have been identified. The binding protein Oct2 also transactivates the VZV ORF62
promoter (25).cloned transcriptional factors CTF (also designated NF-
I), the CCAAT/enhancer binding protein (C/EBP) family, The VZV ORF62 promoter sequence contains a CCAAT
box, positioned between 0117 and 0113 relative to theand NF-Y (also designated CBP or CP-1) recognize cer-
tain CCAAT boxes, although these factors have different transcriptional start site (26, 27), and this sequence was
previously shown to bind a cellular factor(s) in mobilitybinding specificities (2 – 6). All of these CCAAT box-asso-
ciated transcriptional factors have been shown to trans-
activate expression of a variety of genes (6–13), although
TABLE 1C/EBP-a, a member of the C/EBP family, functions as
both a transactivating and a transrepressing factor, de- Oligonucleotides Used for Mobility Shift Assaysa
pending on the target promoters (14).
Oligonucleotide SequenceVaricella-zoster virus (VZV) is a member of the human
a-herpesvirus subfamily. Viral genes of a-herpesviruses 0125 0101
are coordinately expressed and ordered in a cascade
62CCAAT ctag AGTCTCGTCCAATCACTACATCGTCfashion. Immediate-early (IE) genes are the first to be
TCAGAGCAGGTTAGTGATGTAGCAG ctagtranscribed, and are required for expression of the sub- 0125 0101
sequent early and late genes. VZV IE open reading frame
62CCAAT-M ctag AGTCTCGTGATATCACTACATCGTC62 (ORF62) protein transactivates a variety of VZV pro-
TCAGAGCACTATAGTGATGTAGCAG ctag
moters from all three kinetic classes in transient expres- 0109 085
sion assays (15 – 17), and enhances the infectivity of VZV
TK-CCAAT ctag CAGCGTCTTGTCATTGGCGAATTCGvirion DNA (18). VZV ORF62 RNA was also shown to be GTCGCAGAACAGTAACCGCTTAAGC ctag
expressed in human trigeminal ganglia (19), suggesting
that this gene may be expressed during latent infection
C/EBP-C ctag ATGCAGATTGCGCAATCTGCAG
in sensory ganglia. TACGTCTAACGCGTTAGACGTC gact
Expression from the VZV ORF62 promoter is regulated
by viral and host cell proteins. VZV-encoded transactiva-
a Lowercase letters indicate linker sequences, bold letters indicate mu-
tors ORF4, ORF10, and ORF61 proteins transactivate the tated nucleotides, and brackets above or below sequences indicate posi-
tions of putative cis-acting elements. Numbers above sequences indicate
positions relative to the transcriptional start site of the VZV ORF62 gene
(62CCAAT) or the HSV-1 thymidine kinase gene (TK-CCAAT). C/EBP-C1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (301) 496-7383. contains at its center a high-affinity C/EBP binding site (30).
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FIG. 1. (A) A cellular protein binds to the CCAAT box in the VZV IE ORF62 promoter. Protein–DNA binding reactions were performed in 20-ml
reactions containing 12 mM HEPES (pH 7.9), 4 mM Tris–HCl, 1 mM EDTA, 1 mM dithiothreitol, 50 mM KCl, 12% glycerol, 0.25 mg/ml of bovine
serum albumin, 2 mg of poly(dI):(dC), 0.05% NP-40, radiolabeled double-stranded oligonucleotide 62CCAAT (Table 1) (2 1 104 cpm; 0.5 ng), and 5
mg of MeWo cell nuclear extracts (lanes 2–7) or no nuclear extracts (lane 1). Reactions also contained either no additional DNA (lanes 1, 2, and
7) or 100-fold molar excess of unlabeled competitor double-stranded oligonucleotides (lane 3, 62CCAAT; lane 4, TK-CCAAT; lane 5, 62CCAAT-M;
and lane 6, C/EBP-C (Table 1)). The reactions were run on 4% 37.5:1 acrylamide/bis-acrylamide, 0.251 Tris–borate–EDTA gels at 15 V/cm for 2 hr
at 47C. Antibodies to NF-Y (B), but not antibodies to C/EBP-a or CTF (C), supershifted the complex with 62CCAAT. When indicated, normal rabbit
serum (B, lanes 3 and 5; C, lane 2), high-affinity antibody to the B subunit of NF-Y (B, lane 4 (0.02 ml)), rabbit antiserum to the B subunit of NF-Y
(B, lanes 6 (0.1 ml) and 7 (0.2 ml)), monoclonal antibody to the A subunit of NF-Y (B, lanes 8 (0.5 ml) and 9 (1.0 ml)) (36), anti-C/EBP-a antibody (C,
lane 3 (1.0 ml)) (37), or anti-CTF antibody (C, lane 4 (1.0 ml)) was added in the reactions. Arrows indicate the position of specific protein–DNA
complex formed by NF-Y and the 62CCAAT box, and a bracket indicates supershifted NF-Y complexes.
shift assays (28). In this study we show that NF-Y binds bodies to A and B subunits of NF-Y (Fig. 1B), but not
antibodies to CTF or C/EBP-a (Fig. 1C), supershifted ato the CCAAT box, and that mutation of the CCAAT box
abolishes the binding of NF-Y thereby enhancing ORF62 complex, indicating that NF-Y binds to the VZV ORF62
CCAAT box in MeWo (Figs. 1B and 1C) or HeLa cellspromoter activity.
Nuclear extracts were prepared from human malignant (data not shown).
To investigate the ability of NF-Y to regulate expres-melanoma (MeWo) cells which support productive infec-
tion with VZV (29). Radiolabeled double-stranded oligo- sion of the VZV ORF62 gene, we tested a series of
5*-truncation mutants of p62CAT (the VZV ORF62 pro-nucleotide containing the VZV ORF62 CCAAT box
(62CCAAT; Table 1) formed a complex with nuclear ex- moter sequence followed by the chloramphenicol acetyl-
transferase (CAT) gene) for constitutive activity in tran-tracts from MeWo cells (Fig. 1A, lane 2) and HeLa cells
(data not shown). The formation of this complex was sient expression assays. Deletion of an approximately
350-bp region spanning from position 0578 to 0125disrupted by the addition of excess unlabeled oligonucle-
otides containing the VZV ORF62 CCAAT box (62CCAAT) (p62CAT[0124]) reduced the activity of p62CAT (0578)
(which contains the VZV ORF62 promoter sequenceor the herpes simplex virus type 1 (HSV-1) thymidine
kinase (TK) gene CCAAT box (TK-CCAAT; Table 1), but 0578 to /73 nucleotides relative to the transcriptional
start site followed by the CAT gene (24) by approximatelynot those containing the mutated CCAAT box (62CCAAT-
M; Table 1) or the C/EBP-binding consensus sequence 40%. Further deletion from 0124 to 0100 (p62CAT[099]),
including the CCAAT box (positions between 0117 and(C/EBP-C (30); Table 1) (Fig. 1A, lanes 3–6). There was
no specific complex formation using the 62CCAAT-M oli- 0113), enhanced the activity of the ORF62 promoter by
four-fold compared with p62CAT (0124) (Fig. 2). To con-gonucleotide as a probe (data not shown).
To identify the cellular protein which binds to the VZV firm if the CCAAT box contributes to down-regulation of
promoter activity, site-directed mutagenesis of theORF62 CCAAT box in MeWo or HeLa cells, we performed
supershift assays using antibodies raised against CCAAT box sequence was performed. A 3-bp substitu-
tion in the CCAAT box (p62CAT[0578]CCAAT-), whichCCAAT-binding factors CTF/NF-I, C/EBP-a, or NF-Y. Anti-
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